FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $40,214,000 | -33.7% | 1,037,256 | 0.0% | 7.85% | +25.1% |
| Q4 2021 | $60,690,000 | -1.3% | 1,037,256 | 0.0% | 6.28% | -16.7% |
| Q3 2021 | $61,478,000 | -32.0% | 1,037,256 | -0.4% | 7.53% | -16.1% |
| Q2 2021 | $90,392,000 | -2.4% | 1,041,507 | -7.3% | 8.98% | +31.9% |
| Q1 2021 | $92,639,000 | -30.2% | 1,123,576 | -23.0% | 6.81% | -5.9% |
| Q4 2020 | $132,714,000 | +42.2% | 1,459,517 | -37.5% | 7.23% | +5.1% |
| Q3 2020 | $93,360,000 | +16.5% | 2,335,750 | 0.0% | 6.88% | -7.8% |
| Q2 2020 | $80,140,000 | +63.5% | 2,335,750 | +5.8% | 7.46% | +33.9% |
| Q1 2020 | $49,023,000 | +9.6% | 2,207,250 | -3.4% | 5.57% | -25.2% |
| Q4 2019 | $44,731,000 | +26.0% | 2,285,714 | 0.0% | 7.46% | +16.2% |
| Q3 2019 | $35,497,000 | – | 2,285,714 | – | 6.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |